BURZYNSKI RESEARCH INSTITUTE INC
BZYR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BZYR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BZYR
Burzynski Research Institute Inc (BZYR) is a development-stage biotechnology company focused on obtaining FDA approval for its proprietary Antineoplaston therapy, a potential cancer treatment. The company has generated no significant revenue to date and relies on funding from its founder, Dr. Burzynski, to sustain operations.
Key risk: No revenue and negative equity
BioSniper Score
Based on 5 of 6 signals
Market Cap
$1.2M
Cash Runway
0.0 moLead Asset
antineoplastons (Phase 3)
Next Catalyst
Phase3_Topline · Dec 1, 2029Financial data as of Nov 30, 2025.
Tracking 1 pipeline candidate · 3 clinical trials · 1 catalyst for BURZYNSKI RESEARCH INSTITUTE INC.
Burzynski Research Institute Inc (BZYR) is a development-stage biotechnology company focused on obtaining FDA approval for its proprietary Antineoplaston therapy, a potential cancer treatment. The company has generated no significant revenue to date and relies on funding from its founder, Dr. Burzynski, to sustain operations.
- The company has generated no significant revenue since its inception and does not expect operating revenues until Antineoplastons are approved by the FDA [sec_mda · as of 2025-05-20].
- As of November 30, 2025, the company reported cash and equivalents of $0.0M, total revenue of $0.0M, and a net loss of -$0.3M [sec].
- The company's sole source of funding is Dr. Burzynski, who funds operations from his medical practice [sec_mda · as of 2025-05-20].
- A Phase 3 top-line catalyst is scheduled for December 1, 2029, involving a controlled study of combination Antineoplaston therapy [catalyst].
What works
- The company has a defined Phase 3 clinical trial for its Antineoplaston therapy, with a top-line data readout expected on December 1, 2029, indicating progress toward potential FDA approval [catalyst].
- The company's sole funding source, Dr. Burzynski, provides a consistent capital base without reliance on external equity or debt markets, reducing dilution risk [sec_mda · as of 2025-05-20].
What to weigh
- The company has no revenue and a negative shareholders' equity of -$0.0M as of November 30, 2025, indicating a lack of commercial viability and potential solvency concerns [sec].
- The company is entirely dependent on Dr. Burzynski for funding, creating a key-person risk and limiting financial flexibility [sec_mda · as of 2025-05-20].
- The company has no approved products and faces significant regulatory and clinical hurdles before Antineoplastons can be marketed, with no guarantee of success [sec_mda · as of 2025-05-20].
From the filings
Quoted directly from source documents.
The company has no significant revenue and relies on Dr. Burzynski for funding.
“The Company has generated no significant revenue since its inception, and does not expect to generate any operating revenues until such time, if any, as Antineoplastons are approved for use and sale by the FDA. The Company's sole source of funding is Dr. Burzynski, who fund”
SEC MD&A · May 20, 2025
Catalyst timeline
- 2029-12-01 · Phase3_Topline — Top-line results from a controlled Phase 3 study of combination Antineoplaston therapy (Atengenal and Astugenal) are expected, which will be a key efficacy and safety readout.
Risks & what to watch (3)›
Key risks
- No revenue and negative equity — As of November 30, 2025, the company has $0.0M cash, $0.0M revenue, and negative shareholders' equity, indicating financial distress [sec].
- Dependence on single funding source — The company's sole funding is from Dr. Burzynski, creating key-person risk and limiting financial independence [sec_mda · as of 2025-05-20].
- Regulatory and clinical uncertainty — Antineoplastons are not FDA-approved, and the company faces significant hurdles before commercialization, with no guarantee of success [sec_mda · as of 2025-05-20].
What to watch
- Phase 3 top-line data for combination Antineoplaston therapy expected on December 1, 2029 [catalyst].
- Any changes in the company's funding status or reliance on Dr. Burzynski [sec_mda · as of 2025-05-20].
- Updates on FDA interactions or regulatory milestones for Antineoplastons [sec_mda · as of 2025-05-20].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run BURZYNSKI RESEARCH INSTITUTE INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BURZYNSKI RESEARCH INSTITUTE INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
0.0 months
OCF -$823K · Net income -$329K
Lead: Phase 3
1 candidate
1 upcoming, next in ~1189d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for BURZYNSKI RESEARCH INSTITUTE INC?
Burzynski Research Institute Inc (BZYR) is a development-stage biotechnology company focused on obtaining FDA approval for its proprietary Antineoplaston therapy, a potential cancer treatment. The company has generated no significant revenue to date and relies on funding from its founder, Dr. Burzynski, to sustain operations.
What is BURZYNSKI RESEARCH INSTITUTE INC's lead drug candidate?
BURZYNSKI RESEARCH INSTITUTE INC's most advanced tracked candidate is antineoplastons (Phase 3) for cancer.
What is BURZYNSKI RESEARCH INSTITUTE INC's next catalyst?
BURZYNSKI RESEARCH INSTITUTE INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugen" — expected December 1, 2029.
Who is the CEO of BURZYNSKI RESEARCH INSTITUTE INC?
Dr. Stanislaw R. Burzynski M.D., Ph.D. is the chief executive officer of BURZYNSKI RESEARCH INSTITUTE INC (BZYR).
Where is BURZYNSKI RESEARCH INSTITUTE INC headquartered?
BURZYNSKI RESEARCH INSTITUTE INC (BZYR) is headquartered in Houston, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.